[Thrombocyte aggregation and fibrinolysis in healthy probands treated with molsidomine, isosorbide-5-mononitrate and placebo].
Twelve healthy volunteers received either a single oral dose of molsidomine (4 mg), isosorbide-5-mononitrate (ISMN, 20 mg), or placebo in a randomized, double-blind fashion. Blood was drawn prior to, as well as 30 and 60 min after intake of the respective drug. Platelet aggregation and the plasma levels/activity of plasminogen activator (tPA) and its inhibitor (PAI-1) were determined. In contrast to ISMN and placebo, molsidomine provoked a significant reduction in platelet aggregability. No alteration in plasma tPA concentrations was observed independent of whether molsidomine, ISMN, or placebo was applied. However, plasma PAI-1 activity was considerably reduced following molsidomine, but not altered following ISMN or placebo. We conclude that a single oral dose of molsidomine, but not of ISMN inhibits platelet aggregation and increases the fibrinolytic potential in healthy volunteers.
Drummer
C
C
Medizinische Klinik, Klinikum Innenstadt der Universität München.
Valta-Seufzer
U
U
Spannagl
M
M
Frey
A
A
Lüdke
S
S
Schramm
W
W
Gerzer
R
R
D000328:Adult; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives* / Q000494:pharmacology; D008981:Molsidomine / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D010975:Platelet Aggregation Inhibitors; D008981:Molsidomine; D010959:Tissue Plasminogen Activator; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate
Thrombozytenaggregation und Fibrinolyse bei gesunden Probanden unter Molsidomin, Isosorbid-5-mononitrat und Placebo.